SS 42 - Gyn 4: GYN Clinical Trials - Challenging the Paradigm in Gynecologic Cancers

Presentations

• 04:00pm - 05:00pm PT

  Gyn 4: GYN Clinical Trials - Challenging the paradigm in gynecologic cancers

  Speaker: Denise Fabian, MD - University of Kentucky, Lexington
• 04:00pm - 04:10pm PT

  Survival Outcomes of Induction Immunotherapy Combined with Platinum-Based Doublet Chemotherapy Followed by Immunotherapy and Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer: A Phase II Clinical Trial

  Speaker: Yidi Yuan, MD - Peking University Cancer Hospital and Institute, Beijing
• 04:10pm - 04:20pm PT

  Application of Polyethylene Glycol (PEG) Hydrogel in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent Radiation-Induced Rectal Injury: A Multicenter, Randomized, Parallel-Controlled, Prospective, Phase 3 Trial

  Speaker: Junfang Yan, MD - Peking Union Medical College Hospital, Beijing
• 04:20pm - 04:30pm PT

  Phase 3 Study of Pembrolizumab (Pembro) + Adjuvant Chemotherapy (CT) ± Radiotherapy (RT) for Newly Diagnosed, High-Risk Endometrial Cancer (EC): Exploratory Analysis of Disease-Specific-Free Survival (DSFS) and Safety by Radiation Usage

  Speaker: Jyoti Mayadev, MD, FASTRO - UCSD, La JOlla
• 04:30pm - 04:40pm PT

  Nimotuzumab plus Concurrent Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma: Updated Follow-Up from the Randomized, Phase 3 CC3 Study

  Speaker: Junjie Wang, MD, PhD - Peking University Third Hospital, Beijing
• 04:40pm - 04:50pm PT

  The Endoscopy Results of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-Induced Acute Rectal Injury: A Multi-Center, Randomized, Open-Label, Prospective Trial

  Speaker: Jiawei Zhu, MD - Peking Union Medical College Hospital, Beijing
• 04:50pm - 05:00pm PT

  Discussant

  Speaker: Junzo Chino, MD, FASTRO - Duke Cancer Institute, Durham